|
CN102838533A
|
|
Preparation method of roflumilast and key intermediate of roflumilast
|
|
CN102617461A
|
|
Novel method for refining aripiprazole
|
|
CN102417461A
|
|
O-desmethyl-venlafaxine mandelate and preparation method thereof
|
|
CN102327266A
|
|
Pharmaceutical composition containing Iloperidone and preparation method thereof
|
|
CN102727453A
|
|
Blonanserin dispersible tablet and its preparation method
|
|
CN102718711A
|
|
Novel method for preparing (R)-a-amino caprolactam hydrochloride
|
|
CN102552203A
|
|
Pirfenidone tablet and preparation method thereof
|
|
CN101921195A
|
|
Simple method for synthesizing intermediate of retigabine
|
|
CN101919823A
|
|
Medicinal composition for treating thrombus
|
|
CN101822674A
|
|
Iloperidone drug composition and preparation method thereof
|
|
CN101838252A
|
|
2- normal-butyl-5-substituted amino benzofuran and preparation method thereof
|
|
CN102114020A
|
|
Pharmaceutical composition containing besivance or salts thereof and preparation method thereof
|
|
CN102116764A
|
|
Method for determining Adapalene midbody-related substances by using high performance liquid chromatography
|
|
CN102114001A
|
|
Orally administered solid preparation containing tolvaptan
|
|
CN102116765A
|
|
Method for measuring related substance of minodronate intermediate by high performance liquid chromatography
|
|
CN101718751A
|
|
Method for determining desven lafaxine related matters by utilizing high-efficiency liquid-phase chromatography
|
|
CN101716168A
|
|
Medicinal composition containing salt of desmethylvenlafaxine and method for preparing same
|
|
CN101574341A
|
|
Oral solid medicine composition containing ropinirole
|
|
CN101531681A
|
|
High-purity minodronic acid and preparation method thereof
|
|
CN101531601A
|
|
Method for separating and analyzing dopexamine hydrochloride by using HPLC method
|
